Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
ACCESSWIRE•07/08/2026•08:35 ET
0
Whiz Insights
Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategy
Ongoing generation of translational data designed to support future clinical development and deepen understanding of DNase I-mediated NET targeting
Get started
Create a free account to read the full story.